Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

EMPEROR-Reduced: Empagliflozin’s HFrEF benefit holds steady on top of sacubitril/valsartan

Key clinical point: Treatment with sacubitril/valsartan had no significant effect on the safety or efficacy of empagliflozin in patients with HFrEF.

Major finding: Empagliflozin cut the primary endpoint, compared with placebo, by 36% in patients on sacubitril/valsartan, and by 23% among those not on sacubitril/valsartan.

Study details: A post-hoc analysis of data from EMPEROR-Reduced, a multicenter randomized trial with 3,730 patients with heart failure with reduced ejection fraction.

Disclosures: EMPEROR-Reduced was funded by Boehringer Ingelheim and Eli Lilly, the companies that market empagliflozin (Jardiance). Dr. Packer has received personal fees from Boehringer Ingelheim and Eli Lilly and from several other companies.